Kiniksa Pharmaceuticals Ltd (Kiniksa) is a biopharmaceutical company that discovers, acquires, develops and commercializes medicines to treat autoinflammatory and autoimmune diseases. The company's pipeline product portfolio includes Rilonacept drug for the treatment of recurrent pericarditis; mavrilimumab, against giant cell arteritis, COVID-19 and hyper inflammation; vixarelimab, targeting prurigo nodularis and diseases characterized by chronic pruritus; KPL-404, a monoclonal antibody to treat T-cell dependent, B-Cell–mediated indications. It develops medicines in the therapeutic areas of cardiovascular, dermatology and autoimmune diseases. The company operates in Bermuda, the US and the UK. Kiniksa is headquartered in Hamilton, Bermuda.
Kiniksa Pharmaceuticals Ltd premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Pipeline | Arcalyst |
Rilonacept- Recurrent Pericarditis | |
Mavrilimumab- Giant Cell Arteritis, COVID-19 and Chronic Inflammatory Disease | |
XYZ | |
XYZ | |
XYZ |
Competitor Comparison
Key Parameters | Kiniksa Pharmaceuticals Ltd | AbbVie Inc | Sanofi | Novartis AG | Bristol-Myers Squibb Co |
---|---|---|---|---|---|
Headquarters | Bermuda | United States of America | France | Switzerland | United States of America |
City | Hamilton | North Chicago | Paris | Basel | Princeton |
State/Province | - | Illinois | Ile-de-France | - | New Jersey |
No. of Employees | 297 | 50,000 | 87,994 | 76,057 | 34,100 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Sanj K. Patel | Chairman; Chief Executive Officer | Executive Board | 2015 | 53 |
Mark Ragosa | Chief Financial Officer; Senior Vice President | Senior Management | 2021 | 49 |
Eben Tessari | Senior Vice President; Chief Operating Officer | Senior Management | 2022 | 41 |
Michael Megna | Chief Accounting Officer; Vice President - Finance | Senior Management | 2022 | 52 |
Chad Morin | Chief Compliance Officer; Vice President | Senior Management | 2020 | - |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer